Gennova begins enrollment for Phase 1/2 trials of mRNA COVID vaccine
Category: #health  By Mateen Dalal  Date: 2021-04-14
  • share
  • Twitter
  • Facebook
  • LinkedIn

Gennova begins enrollment for Phase 1/2 trials of mRNA COVID vaccine

India's first mRNA-based COVID-19 vaccine, HGCO19, formulated by Pune-based biotech firm, Gennova Biopharmaceuticals is about to enter its Phase 1/2 clinical trials with the enrollment of candidates, said the Department of Biotechnology (DBT).

Reportedly, the Indian regulator (DBT) had prior offered seed funding for this development and is approving additional funding under the 'Mission COVID Suraksha’ program for furthering clinical studies.

In a statement, the DBT asserted that it has been backing Gennova since the beginning of this trial and has facilitated establishing mRNA-based vaccine manufacturing platform by offering seed funding for the development of HGCO19. The biotech firm has collaborated with HDT Biotech Corporation, USA, for the COVID-19mRNA vaccine.

As per reports, HGCO19 has already displayed immunogenicity, safety, neutralization antibody activity in the rodent and non-human primate models.

Commenting on its safety, Sanjay Singh, CEO of Gennova Biopharmaceuticals, affirmed that they have conducted all the required safety assessments of the vaccine as per norms and regulations prior to beginning of the human clinical trial designed to establish the efficacy of HGCO19. Gennova believes the mRNA-based technology will facilitate the development of effective clinical solutions, added Mr. Singh.

Elaborating on their contribution to India’s vaccine development efforts, Renu Swarup, Secretary, DBT, & Chairperson, BIRAC, said that since the onset of COVID-19, DBT has funded many vaccine development programs, which also includes the recent mRNA-based vaccine.

A year ago, mRNA was considered to be a new technology and was never used for vaccine manufacturing in the country. Despite this, the DBT offered funding to Gennova to develop this technology, considering its potential, and is elated to introduce India's first mRNA-based COVID-19 vaccine to clinics.

She added through the Mission COVID Suraksha programme, the DBT has provided support to firms to scale-up production and back clinical studies.

Source Credit: https://www.newindianexpress.com/nation/2021/apr/13/gennova-starts-enrolment-for-phase-12-human-clinical-trials-for-covid-mrna-vaccine-candidate-hgco1-2289531.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Saepio, Echoworx partner to deliver Next-Gen security solutions
Saepio, Echoworx partner to deliver Next-Gen security solutions
By Mateen Dalal

Saepio Information Security, a market leader in statement encryption and cloud-based email, has reportedly announced its collaboration with Echoworx to offer next-generation safe delivery of sensitive and secret information to any email receiver...

Ather Energy raises $250 million to stay ahead in competition
Ather Energy raises $250 million to stay ahead in competition
By Mateen Dalal

Electric scooter producer Ather Energy has reportedly secured $250 million in a new funding round. As per reports, the investment round is in its early stages. The company’s goal is to obtain $200 million to $250 million to compete in the EV...

Digital wellness startup Mojorcare bags USD 20 Mn in Series A funding
Digital wellness startup Mojorcare bags USD 20 Mn in Series A funding
By Mateen Dalal

Mojocare, a wellness and health startup has reportedly raised USD 20.6 million in a Series A round of funding which was led by B Capital Group and saw participation from existing investors including Sequoia India’s Surge, Better Capital, and Ch...